【摘要】

摘要：目的 比较齐拉西酮与奥氮平对女性精神分裂症患者阴阳性症状量表、内分泌代谢和生活质量的影响。
方法 选取我院2015年6月至2017年6月138例女性精神分裂症患者为研究对象，按随机数表法分为齐拉西酮组与奥氮平组，每组69例。齐拉西酮组给予齐拉西酮治疗，奥氮平组给予奥氮平治疗，均持续6周。比较两组精神分裂严重程度，检测患者内分泌代谢指标，统计治疗期间不良反应发生率，评估患者主观舒适度、社会功能及生活质量。
结果 齐拉西酮组治疗6周后阳性与阴性症状评分（PANSS）与奥氮平组比较差异无统计学意义。齐拉西酮组治疗6周后空腹血糖（FBG）、胰岛素抵抗指数（HOMA-IR）、总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白（LDL-C）显著低于奥氮平组（P＜0.05），主观舒适度评分（SWN）显著高于奥氮平组（P＜0.05），生活质量评分（SQLS）显著低于奥氮平组（P＜0.05）。
结论 齐拉西酮与奥氮平对女性精神分裂症患者均具有良好疗效，但齐拉西酮对患者内分泌代谢影响小，在生活质量改善方面具有一定优势。

【Abstract】

Abstract: Objective To compare the effects of ziprasidone and olanzapine on negative-positive symptom scale, endocrine metabolism and quality of life in female patients with schizophrenia.
Methods 138 cases of female patients with schizophrenia from June 2015 to June 2017 in our hospital were selected for the study and divided into ziprasidone group and olanzapine group according to the random number table method, with 69 cases in each group. Ziprasidone group was given ziprasidone, and olanzapine group was given olanzapine, and they were persistently treated for 6 weeks. The severity of schizophrenia was compared between the two groups. The endocrine metabolic indicators were measured, and the incidence rate of adverse reactions during treatment was recorded, and subjective comfort, social function and quality of life were assessed.
Results There was no significant difference in positive and negative symptom scale (PANSS) score between ziprasidone group and olanzapine group after 6 weeks of treatment. The levels of fasting blood glucose (FBG), homeostasis model assessment-insulin resistance index (HOMA-IR), total cholesterol (TC), triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) in ziprasidone group were significantly lower than those in olanzapine group after 6 weeks of treatment (P<0.05), and subjective well-being score (SWN) was significantly higher than that in olanzapine group (P<0.05), and the score of quality of life scale (SQLS) was significantly lower than that in olanzapine group (P<0.05).
Conclusion  s Both ziprasidone and olanzapine have good efficacy on female patients with schizophrenia, but ziprasidone has little effect on endocrine metabolism and has certain advantages in improving the quality of life.